Open Targets brings together a team with expertise from academia and pharma, pulling together skills from a wide range of disciplines including bioinformatics, computer science, web development, human genetics, functional genomics and operations. Our Executive Leadership Team and our Scientific Leadership Team determine the strategic and scientific vision for the consortium and our Strategy and Operations Team provide the necessary support to facilitate the vision and its implementation across our partners.
Our Platform Team and our Genetics Team are responsible for maintaining our informatics resources and tools while our Project Teams conduct experimental and informatics research and our Validation Lab Team takes targets identified from these projects and guides them through further screens to assess suitability for drug discovery programmes.
And our Scientific Advisory Board are a group of well-known individuals from academia and industry that make recommendations to further the sucess of our partnership.
The Open Targets Executive Leadership Team (ELT) provides strategic direction for the partnership, engages with potential new partners, and oversees the awarding of project grants.
The Open Targets Scientific Leadership Team (SLT) is compromised of representatives from every partner and is responsible for setting the scientific priorities for the consortium and approving experimental and informatics research project proposals.
Through our experimental and informatics research programmes, we have funded more that 90 research positions within the institutes that we work with and formed teams that engaged many more scientists across industry and academia to improve target identification and prioritisation.
The Strategy and Operations Team manages our project portfolio, oversees scientific operations and communications, and works with the Executive Leadership Team to develop and implement overall strategy. Our Senior Administrator also provides day-to-day support for senior management.
Regius Professor of Life Sciences
School of Life Sciences, University of Dundee
Vice President, Merck Research Labs (MRL) Head, Genetics and Pharmacogenomics (GpGx)
Merck Research Laboratories
Vice President of Bioinformatics
Assistant Professor of Genetics and of Computer Science
Executive Director, Human Genetics and Senior Fellow, Human Genetics
Interim Director of the Cancer Research UK Cancer Therapeutics Unit and Interim Head of the Division of Cancer Therapeutics
The Institute of Cancer Research
Professor of Genome Sciences
University of Washington